

EXPRESS MAIL CERTIFICATE

Date 5/22/02 Label No. EV028719066-45

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

B.W. LEE
Name (Print)

B.W. Lee
Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE



Docket No.: 3991/OK379

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark Andrew GUTHRIDGE; Michael Claude BERNDT;
Frank Charles STOMSKI; Angel Francisco LOPEZ

Serial No.: 10,099,895

Art Unit: 1645

Confirmation No.: 5422

Filed: March 14, 2002

Examiner:

For: A BINDING MOTIF OF A RECEPTOR

CLAIM FOR PRIORITY

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Applicant hereby claims priority under 35 U.S.C. Section 119 based on Australian patent application No. PQ 2875 filed 15 September 1999 and No. PQ 8733 filed 12 July 2000.

Certified copies of the priority documents are submitted herewith.

Respectfully submitted,

Dated: May 21, 2002

A handwritten signature in dark ink, appearing to read "Paul Fehlner", written over a horizontal line.

Paul F. Fehlner, Ph.D.
Reg. No. 35,135
Attorney for Applicant(s)

DARBY & DARBY P.C.
Post Office Box 5257
New York, NY 10150-5257
212-527-7700

Docket No. 3991/OK379



**Patent Office
Canberra**

I, JONNE YABSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 2875 for a patent by MEDVET SCIENCE PTY LTD filed on 15 September 1999.

WITNESS my hand this
Twelfth day of March 2002

5

JONNE YABSLEY
TEAM LEADER EXAMINATION
SUPPORT AND SALES

AUSTRALIA
Patents Act 1990

PROVISIONAL SPECIFICATION

Invention Title: A BINDING MOTIF OF A RECEPTOR

Applicant: MEDVET SCIENCE PTY LTD

The invention is described in the following statement:

A BINDING MOTIF OF A RECEPTOR

The present invention relates to a binding motif of a receptor. In particular, the binding motif is a cytoplasmic domain associated with stimulation of receptor mediated activities. The present invention further contemplates methods of using the motif in particular for mediating activities of receptors.

INTRODUCTION

The action of signalling molecules such as cytokines has been poorly understood. It is apparent that these cellular proteins can switch on activities within cells. However, the actual triggering mechanisms and how these are relayed to culminate in their final activities is not known. Cell cycles are clearly involved but the link between the triggering molecule and receptor and actions such as cell survival, proliferation, and differentiation is unclear.

Proteins including human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 are capable of stimulating normal and transformed hematopoietic cells. With each, the initiating event for signal transduction is the binding of the protein to their surface receptors. These receptors may be composed of subunits such as the α chain and a common β chain (β_c). Engagement of β_c by the binding of the cytoplasmic protein to surface receptors results in the stimulation of cell survival, proliferation, and differentiation and mature cell effector function in the appropriate lineage, a fact that emphasises the major signaling role played by β_c in mediating receptor induced biological activities.

One of the first events in activation of receptors and in the initiation of the signaling cascade is tyrosine phosphorylation of β_c . This is a common theme among receptor signaling subunits and can be seen in homodimeric receptors such as the erythropoietin (EPO) receptor, thrombopoietin (TPO) receptor, and granulocyte colony-stimulating factor (G-CSF) receptor as well as in heterodimeric

receptors such as in the IL-6 and IL-2 receptors, and in the GM-CSF, IL-3, and IL-5 receptor systems.

5 Tyrosine phosphorylation of receptor signaling subunits appeared to be a critical step in the creation of docking sites for the association of signaling molecules. Despite the perceived importance of tyrosine phosphorylation of receptors, it is becoming apparent that signaling can proceed in its absence. This is demonstrated in the EPO and TPO receptors, in which the substitution of all tyrosines failed to abolish their activities.

10

It has been unclear until now how the binding of proteins to their receptors can result in the specialised functions associated with these molecules and their receptors. The signaling events which lead to the specialised functions are unknown. However various cellular proteins are implicated in the cascade of events culminating in the biological functions associated with various molecules. There are many ubiquitous proteins involved in cell signaling pathways and any one or more may be involved in relaying signals switched on by proteins binding to their receptor.

20 The 14-3-3 family of proteins is one such protein, which consists of 7 different isoforms and is expressed ubiquitously from yeast to humans. The ability of 14-3-3 to bind to a number of motifs in a wide range of signaling molecules suggests that 14-3-3 proteins may participate in a number of cell signaling pathways that may include mitogenesis, transformation and survival. Although 14-3-3 has been shown to bind a number of signaling molecules, it has been more difficult to determine how or where 14-3-3 can regulate signaling events directly or indirectly, or whether 14-3-3 is implicated at all.

30 Accordingly, an object of the present invention is to overcome some of the problems of the prior art and to understand how proteins can express their biological activities and to use this information to manipulate cellular functions.

SUMMARY OF THE INVENTION

In one aspect of the present invention, there is provided a binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a functional equivalent or
 5 analogue thereof and wherein at least two (2) of the at least five (5) amino acids are serine.

The receptor may be any receptor that is capable of binding to an extracellular protein and which mediates its function through the binding of a cytoplasmic
 10 protein such as 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. More preferably, the cytoplasmic protein is 14-3-3.

15

Preferably the receptor is selected from the group including:

- (1) GM-CSF/IL-3/IL-5 receptor
- (2) IL6 human interleukin-6 receptor beta chain precursor (IL-6R-beta)
- 20 (3) LEPR human leptin receptor precursor (LEP-R) (OB RECEPTOR) (OB-R).
- (4) TNFR2 human tumor necrosis factor receptor 2 precursor (tumor necrosis factor
- (5) VGR1 human vascular endothelial growth factor receptor 1 precursor
- (6) TRK3 human receptor protein-tyrosine kinase TKT precursor (EC
 25 2.7.1.112)
- (7) Q01974 protein-tyrosine kinase transmembrane receptor ROR2 precursor
- (8) FGR1 human basic fibroblast growth factor receptor 1 precursor (BFGF-R)
- (9) Q15426 protein-tyrosine phosphatase, receptor-type, H precursor (EC 3.1.3.48)
- 30 (10) PTPM human protein-tyrosine phosphatase mu precursor (EC 3.1.3.48) (R-PTP-MU).

- (11) PGDS human alpha platelet-derived growth factor receptor precursor (EC 2.7.1.112)
- (12) IG1R human insulin-like growth factor i receptor precursor (EC 2.7.1.112).
- (13) FGR4 human fibroblast growth factor receptor 4 precursor (FGFR-4) (EC 2.7.1.112)
- (14) FGR2 human fibroblast growth factor receptor 2 precursor (FGFR-2) (EC 2.7.1.112)
- (15) Q13635 patched protein homolog (PTC)
- (16) MANR human macrophage mannose receptor precursor.
- (17) LRP2 human low-density lipoprotein receptor-related protein 2 precursor (megalin)
- (18) IDD human integral membrane protein dgcr2/idd precursor (KIAA0163)
- (19) AMFR human autocrine motility factor receptor precursor (AMF receptor) (gp78)
- (20) ACH5 human neuronal acetylcholine receptor protein, alpha-5 chain precursor.
- (21) KKIT human: stem cell growth factor receptor (proto-oncogene tyrosine-protein kinase kit) (C-KIT) (CD117 antigen)
- (22) TPOR human: thrombopoietin receptor precursor (TPO-R) (myeloproliferative leukemia protein (C-MPL). (TPOR or MPL).
- (23) TPOR mouse: thrombopoietin receptor precursor (TPO-R) (myeloproliferative leukemia protein) (C-MPL). (TPOR or MPL).

Preferably, the binding motif of the receptor is capable of interacting with a cytoplasmic protein such as 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. More preferable, the cytoplasmic protein is 14-3-3.

30

Preferably the binding motif of a receptor has an amino acid sequence selected from the group including:

	6
	(i) HSRSLP
	(ii) SSSRP
	(iii) SNSKP
	(iv) SDSSP
5	(v) SISAP
	(vi) SLSLP
	(vii) SASTP
	(viii) SPSFP
	(ix) SNSQP
10	(x) SVSSP
	(xi) STSVP
	(xii) SKSPP
	(xiii) SRSQP
	(xiv) SSSLP
15	(xv) SSSGP
	(xvi) SSSFP
	(xvii) SPSYP
	(xviii) SGSLP
	(xix) SQSSP
20	(xx) SPSLP
	(xxi) SGSTP
	(xxii) SVSPP
	(xxiii) SGSGP
	(xxiv) SLGSSP
25	(xxv) SSSQP
	(xxvi) KSSERTP
	(xxvii) KSSESTP

or a functional equivalent or analogue thereof.

30 In another aspect of the present invention, there is provided a phosphorylated binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a

functional equivalent or analogue thereof and wherein at least two (2) of the at least five (5) amino acids is a serine and wherein at least one serine residue of the motif is phosphorylated.

- 5 In a further preferred aspect, there is provided a binding motif of a GM-CSF/IL-3/IL-5 receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least ⁵⁸²HSRSLP⁵⁸⁷ of the GM-CSF/IL-3/IL-5 receptor or a functional equivalent or analogue thereof wherein at least Ser⁵⁸⁵ is phosphorylated.

10

In another aspect of the present invention, there is provided a method of binding a cytoplasmic protein to a receptor, said method comprising:

- phosphorylating a binding motif of a receptor as described above, a
15 functional equivalent or analogue thereof; and

subjecting the binding motif of the receptor to a cytoplasmic protein.

- 20 In another aspect of the present invention, there is provided a method of phosphorylating a binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a functional equivalent or analogue thereof and wherein at least two (2) of the at least five (5) amino acids are serine, said method comprising binding a triggering molecule to the receptor.

25

In another aspect of the present invention, there is provided a method of activating cellular activities said method including:

- phosphorylating a binding motif of a receptor as described above, a
30 functional equivalent or analogue thereof; and

subjecting the binding motif to a cytoplasmic protein, wherein said cytoplasmic protein is associated with activation of cellular activities.

In yet another aspect of the present invention there is provided a method of regulating cellular activities, said method including:

phosphorylating a binding motif of a receptor as described above, a functional equivalent or analogue thereof; and

subjecting the binding motif to a cytoplasmic protein to bind the cytoplasmic protein to the binding motif; and

activating a cell signaling pathway by interacting the bound cytoplasmic protein with a signaling molecule involved in the pathway.

IN THE FIGURES

Figure 1 shows the amino acid sequence of the common β chain (β_c).

Figure 2 shows the amino acid sequence of the Stem Cell Growth Factor Receptor (Proto-Oncogene Tyrosine- Protein Kinase Kit) (C-KIT) (CD 117 Antigen)

Figure 3 shows the amino acid sequence of the Human Thrombopoietin Receptor Precursor (TPO-R) (Myeloproliferative Leukaemia Protein) (C-MPL).

Figure 4 shows the amino acid sequence of the Mouse Thrombopoietin Receptor Precursor (TPO-R). (Myeloproliferative Leukaemia Protein) (C-MPL).

Figure 5 shows that Human β_c associates with 14-3-3 ζ and this association is mediated by the 544-626 region of β_c . HEK 293T cells were either mock transfected (mock), transfected with wild type β_c (wt) or β_c containing C terminal deletions. Lysates were prepared from transfected cells and either immunoprecipitated with anti-14-3-3 ζ antibody (A) or precipitated with either 14-3-3-GST sepharose (B) or GST-sepharose (C). All proteins were separated on

7.5% SDS-PAGE under reducing conditions before Western blotting with anti- β_c antibody (MAb 1C1).

Figure 6 shows that 14-3-3 ζ specifically binds the HSRSLP motif of the β_c cytoplasmic domain. (A) HEK 293 cells were used either untransfected (UT), or transfected with wild type β_c (wt), or with β_c containing the sequence ⁵⁸¹PHSRSLP⁵⁸⁷ mutated to ⁵⁸¹GEFAAAA⁵⁸⁷ or with β_c containing the sequence ⁸²⁰RSKPSSP⁸²⁶ mutated to ⁸²⁰EFAAAAA⁸²⁶. Lysates were made and immunoprecipitations were performed using GST-14-3-3-sepharose. The presence of β_c was determined by Western blotting with an anti- β_c antibody (MAb 1C1). (B) The level of expression β_c in the lysates was determined by Western blotting with an anti- β_c antibody (MAb 1C1).

Figure 7 shows that Inhibition of β_c association with 14-3-3 ζ by phosphorylated but not by unphosphorylated β_c and raf-1 peptides. Lysates of HEK293T cells transfected with β_c were immunoprecipitated with GST-14-3-3-sepharose in the absence or in the presence of chemically-synthesised peptides (100uM) containing a β_c sequence (CLGPPHSRSLPDILG) or a Raf-1 sequence (CLSQRQRSTSTPNVHM). In the phosphorylated peptides the relevant phosphorylated serine is underlined. The experiment was performed on 7.5% SDS-PAGE under reducing conditions. The presence of β_c in the precipitation experiment was determined by Western blotting with anti- β_c antibody (MAb 1C1).

Figure 8 shows that Specific inhibition of β_c association with 14-3-3 ζ by a phosphorylated peptide encompassing the 579-592 region of β_c . Lysates of HEK293T cells transfected with β_c were precipitated with GST-14-3-3-sepharose in the absence or in the presence of various concentrations of chemically-synthesised peptides. Two β_c peptide sequences were used, CLGPPHSRSLPDILG either non phosphorylated (A) or serine⁵⁸⁵ phosphorylated (B), and CPLSLRSKPSGPGP either non phosphorylated (C) or serine phosphorylated (D). The appropriate phosphorylated serine in each peptide is underlined. The experiment was performed on 7.5% SDS-PAGE under reducing

conditions. The presence of β_c in the immunoprecipitates was determined by Western blotting with anti- β_c antibody (MAb 1C1).

Figure 9 shows that Binding of ^{125}I -labeled 14-3-3z to synthetic peptides corresponding to the 14-3-3 binding region of β_c . Microtiter wells were coated with synthetic peptides CLGPPHSRSLPDILG either non phosphorylated or phosphorylated on the second serine (underlined). Various concentrations of ^{125}I -labeled recombinant 14-3-3z protein were added to microtiter wells and incubated at 22°C for 2 h. Insert: Scatchard analyses of 14-3-3 interaction with the serine-phosphorylated peptide.

Figure 10 shows that ^{585}Ser in β_c is phosphorylated *in vivo* by GM-CSF. (A) The anti-phospho- $^{585}\text{Ser}\beta_c$ antibody specifically recognises the phosphorylated CLGPPHSRSLDILG peptide. Dot blots were prepared on nitrocellulose filters of either the non phosphorylated or the serine phosphorylated CLGPPHSRSLPDILG peptide and the scrambled peptide CLPLSGPD^{SHIR}GPL before probing with anti-phospho- $^{585}\text{Ser}\beta_c$ antibody. (B) The serine phosphorylated CLGPPHSRSLPDILG peptide specifically inhibits the binding of anti-phospho- $^{585}\text{Ser}\beta_c$ antibody to β_c . Lysates of HEK293T cells transfected with wild type β_c were immunoprecipitated with anti- β_c antibody (MAb 8E4). Immunoprecipitates were run on 7.5% SDS-PAGE under reducing conditions. Anti-phospho- $^{585}\text{Ser}\beta_c$ antibody was then pre-incubated with either medium (none), 100 fold molar excess of the serine phosphorylated (1) or non phosphorylated (2) CLGPPHSRSLPDILG peptide, or the scrambled peptide CLPLSGPD^{SHIR}GPL (3). The filters were then Western blotted and probed with the pretreated anti-phospho- $^{585}\text{Ser}\beta_c$ antibody. (C) Upregulation of ^{585}Ser phosphorylation by GM-CSF. M1 cells expressing GM-CSFRa and β_c were either untreated (-) or stimulated with GM-CSF (2ng/ml) for 30 seconds (+). Lysates of the M1 cells were immunoprecipitated with anti- β_c antibody (MAb 8E4) and the immunoprecipitates run on 10% SDS-PAGE under reducing conditions. The filters were then Western blotted with either anti-phospho- $^{585}\text{Ser}\beta_c$ antibody or the anti- β_c antibody (MAb 1C1).

Figure 11 shows Phosphorylation of Ser585 of β_c in response to IL-3 and the recruitment of 14-3-3. CTL-EN cells expressing IL-3Ra and either wt β_c or β_c HSRSLPmEFAAAA were washed, starved for 4 hours in DMEM containing 0.1% FCS and then stimulated with 50ng/ml IL-3 for the indicated times. Cells were then lysed and the β_c immunoprecipitated (7×10^7 cells/IP) with the 1C1 anti- β_c specific mAb. Immunoprecipitates were divided and 80% or 20% were separately run on SDS-PAGE and transferred to nitrocellulose filters. (a) 80% of the immunoprecipitates were probed with the anti-phospho-Ser585 β_c antibody, the filters stripped, and reprobed with the 1C1 anti- β_c mAb. 20% or the immunoprecipitates were probed with the 4G10 anti-phosphotyrosine antibody. (b) Regulation of 14-3-3 association with β_c following IL-3 stimulation. CTL-EN cells were starved and stimulated as above, and β_c was immunoprecipitated with the 1C1 mAb coupled to Sepharose beads. Immunoprecipitates were boiled in a non-reducing sample buffer and subjected to SDS-PAGE on a non-reducing gel. Immunoblot analysis was performed with anti-14-3-3 antibodies and the filter stripped and re-probed with the 1C1 antibody. These results were typical of 3 experiments.

Figure 12 shows PKA phosphorylates Ser585 of β_c . a) The ability of either PKA or CKII to phosphorylate purified his β_c 445-881 was examined in an *in vitro* kinase assay using g^{32} PATP. Peptide competitions were also performed using 200mM peptides containing the indicated sequences. b) The ability of PKA and CKII to phosphorylate Ser585 of his β_c 445-881 was examined by immunoblot analysis using the anti-phospho-Ser585 β_c antibodies. Filters were probed firstly with anti-phospho-Ser585 β_c antibodies (top panel). Filters were then stripped and re-probed with an antibody that recognizes the HSRSLP motif of β_c regardless of whether Ser585 is phosphorylated or not (anti-HSRSLP β_c)(bottom panel). c) To determine if agents that elevate intracellular cAMP and activate PKA also resulted in increased phosphorylation of β_c Ser585, cells were starved for 12 hours and left unstimulated (nil), or stimulated with IL-3 (50ng/ml), forskolin (50mM) or dibutyryl cAMP (100mM) for 10 minutes at 37°C. Cells were then lysed and β_c

immunoprecipitated with 1C1. Ser585 phosphorylation of β_c was determined using the anti-phospho-Ser585 antibodies (top panel). The filter was then stripped and re-probed with anti β_c 1C1 antibodies.

- 5 Figure 13 shows 14-3-3 binding to β_c in response to IL-3 stimulation is required for the recruitment and activation of PI 3-kinase. (a) analysis of PI 3-kinase activity. CTL-EN cells expressing IL-3Ra and either wt β_c or β_c HSRSLPmEFAAAA were starved for 12 hours in DMEM containing 0.5% FCS and stimulated with 50ng/ml IL-3 for the indicated times. Cells were then lysed and phospho-tyrosine containing proteins were immunoprecipitated (2x10⁷ cells/IP) using the 4G10 antibody. Immunoprecipitates were washed in 1x PI 3-kinase buffer (20mM HEPES, pH 7.5, 5mM MgCl₂, 1mM EGTA) and PI 3-kinase activity was analysed in a lipid kinase assay using phosphatidyl inositol and g³²PATP as substrates as described in the "Materials and Methods".
- 10 15 Autoradiogram of TLC plate is shown with ³²P-labelled phosphatidyl inositols (PIP) and the origin indicated. These results were typical of 3 experiments. (b) CTL-EN cells were also examined for the association of β_c with p85. CTL-EN cells expressing either wt β_c or β_c HSRSLPmEFAAAA were starved for 12 hours in DMEM containing 0.5% FCS and then stimulated with 50ng/ml IL-3 for the indicated times. Cells were then lysed and the β_c immunoprecipitated (2x10⁷ cells/IP) with the 1C1 anti- β_c specific mAb. Immunoprecipitates were then subjected to SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-p85 (1mg/ml) followed by detection with HRP-conjugated anti-rabbit IgG antibody and ECL. The filters were then stripped, probed with anti-SHP2 (1mg/ml), stripped again and finally probed with 1C1 anti- β_c (2mg/ml). These results were typical of 2 experiments. The association of his β_c 445-881 with p85 was also assessed in pull-down experiments together with peptide competition. (c) List of peptides used in the his β_c 445-881 pull-down experiment. S refers to a phospho-serine residue. (d) Association of p85 with recombinant his β_c 445-881. his β_c 445-881 (10mg) coupled to Sepharose resin and phosphorylated on Ser585 with PKA (lanes 1-5) or Sepharose alone (lane 6) was incubated with COS-7 pre-cleared lysates in the absence (lane 1) or in the presence of 200mM competing
- 20 25 30

peptides (lane 2, scrambled. lane 3, Ser585Ala. lane 4, non-phospho-Ser585. lane 5, phospho-Ser585) for 1 hour at 4°C. The resin was then washed extensively, subjected to SDS-PAGE and transferred to a nitrocellulose filter. The filter was immunoblotted with anti-p85 antibodies (1mg/ml) followed by detection
 5 with HRP-conjugated anti-rabbit IgG antibody and ECL. These results were typical of 2 experiments.

Figure 14 shows 14-3-3 binding to β_c is required for Akt activation but not STAT5, ERK or JNK activation. (a) CTL-EN cells expressing IL-3Ra and either wt β_c or
 10 β_c HSRSLPmEFAAAA were starved for 12 hours in DMEM containing 0.5% FCS and then stimulated with 50ng/ml IL-3 for the indicated times. Cells were lysed, whole cell lysates were subjected to SDS-PAGE and transferred to a nitrocellulose filter. Filters were immunoblotted and stripped sequentially with anti-phospho Akt pAb (1:500) anti-phosphorylated STAT5 mAb (2mg/ml), anti-
 15 active MAPK pAb (50ng/ml) and anti-ERK pAb (1mg/ml) followed by detection with HRP-conjugated anti-rabbit or anti-mouse IgG antibody and ECL. (b) CTL-EN cells expressing IL-3Ra and either wt β_c or β_c HSRSLPmEFAAAA were starved for 12 hours in DMEM containing 0.5% FCS and stimulated with 50ng/ml IL-3 for the indicated times. Cells were lysed and JNK was immunoprecipitated. The
 20 immunoprecipitates were then washed in 1x JNK buffer (10mM MgCl₂, 10mM Tris-HCl pH 7.4) and the JNK activity was then analysed in an *in vitro* kinase assay using γ -³²PATP and 1mg GST-jun1-79. Kinase assays were subjected to SDS-PAGE and transferred to a nitrocellulose filter. An autoradiogram of the filters is shown.

25

Figure 15 shows 14-3-3 binding to β_c in response to IL-3 regulates cellular viability. (a) CTL-EN cells expressing IL-3Ra and either wt β_c or
 β_c HSRSLPmEFAAAA were washed and then plated in duplicate at 2.5×10^5 cells/ml in DMEM containing 0.1% FCS and either 10ng/ml IL-3, 10 ng/ml IL-2 or
 30 10ng/ml IL-3 and 5 mM LY294002. Viable cells were counted using the trypan blue exclusion method after 4 days. The results shown are typical of 3 experiments. (b) CTL-EN cells expressing IL-3Ra and either wt β_c or

β_c HSRSLPmEFAAAA were washed and then plated in triplicate at 5×10^5 cells/ml in DMEM containing 0.1% FCS and either no IL-3, 1ng/ml IL-3 or 10ng/ml IL-3. Metabolic activity was measured each day using the CellTiter96 AQueous one solution cell proliferation assay according to the manufacturers instructions.

5 Shown are the raw absorbance values (490nm) plotted against day for CTL-EN cells expressing wt β_c in the presence of no IL-3 (u), 1ng/ml IL-3 (l) or 10ng/ml IL-3 (n) and CTL-EN cells expressing the β_c HSRSLPmEFAAAA mutant in the presence of no IL-3 (u) or 10 ng/ml IL-3 (t). These results are typical to 2 experiments.

10

Figure 16 shows 14-3-3 binding to β_c is not required for cell cycle progression. a) CTL-EN cells expressing IL-3Ra and either wt β_c or β_c HSRSLPmEFAAAA were washed and then plated at 2.5×10^5 cells/ml in DMEM containing 0.1% FCS and starved for 24 hours. Cells were then stimulated for a further 24 hours with 50
15 ng/ml IL-3 in the same medium after which the cells were harvested by centrifugation, fixed in ethanol and stained with propidium iodide. Cell cycle distribution was then analysed by flow cytometry. b) c-myc induction in response to IL-3 stimulation. CTL-EN cells were washed, starved and stimulated with IL-3 for 2 hours as described above. Total RNA was extracted and subjected to
20 Northern blot analysis. Filters were probed sequentially with 32 P-labelled cDNAs for c-myc and 18SrRNA. Signals were detected by autoradiography.

Figure 17 shows 14-3-3 binding to β_c in response to IL-3 stimulation promotes cellular survival by suppressing apoptosis. CTL-EN cells expressing IL-3Ra and
25 either wt β_c or β_c HSRSLPmEFAAAA were washed and then plated at 5×10^5 cells/ml in DMEM containing 0.1% FCS and either 10ng/ml IL-3 or 10 ng/ml IL-2 for 18 hours. Cells were then harvested by centrifugation and stained with annexin V according to the manufacturers instructions. Annexin V positive cells were then analysed by flow cytometry.

30

Figure 18. Proposed model for the regulation of survival by IL-3. Binding of IL-3 to the IL-3 receptor, composed of an α -chain (α) and a β -Chain (β_c), results in

receptor oligomerization (only one α -chain and one β -chain are shown for simplicity), increased tyrosine phosphorylation and also increased Ser585 phosphorylation (S). Ser585 phosphorylation of β_c allows recruitment of 14-3-3, which in turn recruits PI 3-kinase (PI 3-K) either directly, or indirectly through an additional adaptor molecule. The recruitment of PI 3-kinase and the production of phosphatidylinositols (PIP) couples the activated receptor to downstream signalling molecules such as Akt and promotes cellular survival.

Figure 19. ^{585}Ser in β_c of acute myeloid leukaemia (AML) is constitutively phosphorylated. CTL-EN cells expressing IL-3R α and β_c were either untreated or stimulated with IL-3 (2ng/ml) for 1 or 5 minutes. AML cells expressing GM-CSFR α and β_c were either untreated or stimulated with GM-CSF (2ng/ml) for 5 minutes. Lysates of either CTL-EN cells or AML cells were immunoprecipitated with anti- β_c antibody (MAb 8E4) and the immunoprecipitates run on 10% SDS-PAGE under reducing conditions. The filters were then western blotted with either anti-phospho- $^{585}\text{Ser}\beta_c$ antibody (A) or the anti- β_c antibody (MAb 1C1) (B).

DETAILED DESCRIPTION OF THE INVENTION

In one aspect of the present invention, there is provided a binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a functional equivalent or analogue thereof and wherein at least two (2) of the at least five (5) amino acids are serine.

The term "functional equivalent or analogue thereof" as used herein means a sequence which functions in a similar way but may have deletions, additions or substitutions that do not substantially change the activity or function of the sequence.

The term "comprising" or "comprises" or variations of the word as used herein is not intended to exclude other additives, components, integers or steps.

The term "motif" as used herein in relation to the receptor, means a distinctive portion of the receptor but is not intended to include the whole receptor.

The receptor may be any receptor that is capable of binding to an extracellular protein and which mediates its function through the binding of a cytoplasmic protein such as 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. More preferably, the cytoplasmic protein is 14-3-3.

Signaling molecules may be molecules involved in cellular pathways such as those pathways involved in proliferation, survival or differentiation. Examples of such pathways may include the JAK/STAT pathway, the ras/MAP kinase pathway or the PI-3-Kinase pathway. All pathways may be involved directly or indirectly with these functions.

Preferably the receptor is selected from the group including:

- (1) GM-CSF/IL-3/IL-5 receptor
- (2) IL6 human interleukin-6 receptor beta chain precursor (IL-6R-beta)
- (3) LEPR human leptin receptor precursor (LEP-R) (OB RECEPTOR) (OB-R).
- (4) TNR2 human tumor necrosis factor receptor 2 precursor (tumor necrosis factor
- (5) VGR1 human vascular endothelial growth factor receptor 1 precursor
- (6) TRK3 human receptor protein-tyrosine kinase TKT precursor (EC 2.7.1.112)
- (7) Q01974 protein-tyrosine kinase transmembrane receptor ROR2 precursor
- (8) FGR1 human basic fibroblast growth factor receptor 1 precursor (BFGF-R)
- (9) Q15426 protein-tyrosine phosphatase, receptor-type, H precursor (EC 3.1.3.48)

- (10) PTPM human protein-tyrosine phosphatase mu precursor (EC 3.1.3.48) (R-PTP-MU).
- (11) PGDS human alpha platelet-derived growth factor receptor precursor (EC 2.7.1.112)
- 5 (12) IG1R human insulin-like growth factor i receptor precursor (EC 2.7.1.112).
- (13) FGR4 human fibroblast growth factor receptor 4 precursor (FGFR-4) (EC 2.7.1.112)
- (14) FGR2 human fibroblast growth factor receptor 2 precursor (FGFR-2) (EC 2.7.1.112)
- 10 (15) Q13635 patched protein homolog (PTC)
- (16) MANR human macrophage mannose receptor precursor.
- (17) LRP2 human low-density lipoprotein receptor-related protein 2 precursor (megalin)
- (18) IDD human integral membrane protein dgcr2/idd precursor (KIAA0163)
- 15 (19) AMFR human autocrine motility factor receptor precursor (AMF receptor) (gp78)
- (20) ACH5 human neuronal acetylcholine receptor protein, alpha-5 chain precursor.
- (21) KKIT human: stem cell growth factor receptor (proto-oncogene tyrosine-protein kinase kit) (C-KIT) (CD117 antigen)
- 20 (22) TPOR human: thrombopoietin receptor precursor (TPO-R) (myeloproliferative leukemia protein (C-MPL). TPOR or MPL.
- (23) TPOR mouse: thrombopoietin receptor precursor (TPO-R) (myeloproliferative leukemia protein) (C-MPL). TPOR or MPL.

25

Preferably, the binding motif of the receptor is capable of interacting with a cytoplasmic protein such as 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis,

30 proliferation, transformation, differentiation and cell survival. More preferably, the cytoplasmic protein is 14-3-3.

The 14-3-3 protein is a family of proteins which consists of 7 different isoforms and is expressed ubiquitously from yeast to humans. The ability of 14-3-3 to bind to a number of motifs in a wide range of signaling molecules suggests that 14-3-3 proteins may participate in a number of cell signaling pathways that may include mitogenesis, transformation and survival. Although 14-3-3 has been shown to bind a number of signaling molecules, it has been more difficult to determine how 14-3-3 can regulate signaling events.

Preferably the binding motif of a receptor has an amino acid sequence selected from the group including:

- | | | |
|----|---------|--------|
| | (i) | HSRSLP |
| | (ii) | SSSRP |
| | (iii) | SNSKP |
| | (iv) | SDSSP |
| 15 | (v) | SISAP |
| | (vi) | SLSLP |
| | (vii) | SASTP |
| | (viii) | SPSFP |
| | (ix) | SNSQP |
| 20 | (x) | SVSSP |
| | (xi) | STSVP |
| | (xii) | SKSPP |
| | (xiii) | SRSQP |
| | (xiv) | SSSLP |
| 25 | (xv) | SSSGP |
| | (xvi) | SSSFP |
| | (xvii) | SPSYP |
| | (xviii) | SGSLP |
| | (xix) | SQSSP |
| 30 | (xx) | SPSLP |
| | (xxi) | SGSTP |
| | (xxii) | SVSPP |

- (xxiii) SGSGP
- (xxiv) SLGSSP
- (xxv) SSSQP
- (xxvi) KSSERTP
- (xxvii) KSSESTP

5

or a functional equivalent or analogue thereof.

The binding capacity of the motif may be analysed by any binding studies or experiments available to the skilled addressee. Such experiments may include measuring the binding ability of a designated cytoplasmic protein to the binding motif. For instance electrophoretic mobility shift assays (EMSA or band shift assays) or foot print assays are available to measure specific binding.

10

Hence the binding motif can be identified by the number of amino acids, serine residues and the ability to bind a designated cytoplasmic protein. The designated cytoplasmic protein may be 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. More preferable, the cytoplasmic protein is 14-3-3.

15

20

Preferably, the receptor is the GM-CSF/IL-3/IL-5 receptor which includes the common beta chain (β_c). It is found that the cytokines GM-CSF, IL-3 and IL-5 signal their actions through the surface receptor via the β_c . Most preferably, the binding motif comprises a sequence of at least amino acids HSRSL corresponding to amino acids 582 to 587 of the common β_c according to Figure 1 a functional equivalent or analogue thereof.

25

The common β chain (β_c) is a component of a cytokine receptor and is part of a signaling subunit of the receptor. It is thought that the cytokine signals its functions through the β_c , initiating events which cascade and culminate in an identifiable biological function such as cell survival, proliferation, differentiation

30

and mature cell effector functions. However, the present invention is not limited to motifs of the β_c but includes motifs of receptors having similar sequences to the β_c .

- 5 The region or motif comprising amino acids 582 to 587 of the common β_c may include ⁵⁸²HSRSL⁵⁸⁷ which preferably interacts with a cytoplasmic protein selected from the group including 14-3-3 protein, WW-domain of the prolyl isomerase, Pin1, and the ubiquitin ligase, NEDD4 or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of
- 10 events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. However the present invention is not limited to this sequence but includes other equivalent sequences capable of performing the same function.

- 15 Other binding motifs of receptors according to the present invention include amino acid sequences of:

Stem Cell Growth Factor Receptor (C-Kit) (Proto-Oncogene Tyrosine- Protein Kinase Kit) (C-KIT) (CD 117 Antigen), preferably including amino acids 863 to 869

20 according to Figure 2 or amino acid residues 965 to 969 according to Figure 2 or a functional equivalent or analogue thereof.

Thrombopoietin Receptor Precursor (TPO-R) (Myeloproliferative Leukemia Protein) (C-MPL). (TPOR or MPL) preferably including amino acids 573 to 579

25 according to Figure 3 or a functional equivalent or analogue thereof.

Thrombopoietin Receptor Precursor (TPO-R) (Myeloproliferative Leukemia Protein) (C-MPL). (TPOR or MPL) preferably including amino acids 564 to 570

30 according to Figure 4 or a functional equivalent or analogue thereof.

IL6B HUMAN interleukin-6 receptor beta chain precursor (IL-6R-BETA),
preferable including amino acids 735- 739 having the sequence SSSRP or a
functional equivalent or analogue thereof

- 5 LEPR HUMAN leptin receptor precursor (LEP-R) (OB receptor) (OB-R),
preferably including amino acids 991- 995 having the sequence SNSKP or a
functional equivalent or analogue thereof.

- 10 TNR2 HUMAN tumor necrosis factor receptor 2 precursor (tumor necrosis factor)
preferably including amino acids 368- 372 having the sequence SDSSP or a
functional equivalent or analogue thereof.

- 15 VGR1 HUMAN vascular endothelial growth factor receptor 1 precursor, preferably
including amino acids 1197- 1201 having the sequence SISAP or a functional
equivalent or analogue thereof.

- 20 TRK3 HUMAN receptor protein-tyrosine kinase TKT precursor (EC 2.7.1.112),
preferably including amino acids 444- 448, having the sequence SLSLP or a
functional equivalent or analogue thereof.

Q01974 protein-tyrosine kinase transmembrane receptor ROR2 precursor,
preferably including amino acids 435- 439, having the sequence SASTP or a
functional equivalent or analogue thereof.

- 25 FGR1 HUMAN basic fibroblast growth factor receptor 1 precursor (BFGF-R),
preferably including amino acids 777- 781, having the sequence SPSFP or a
functional equivalent or analogue thereof.

- 30 Q15426 protein-tyrosine phosphatase, receptor-type, H precursor (EC 3.1.3.48),
preferably including amino acids 1082- 1086, having the sequence SNSQP or a
functional equivalent or analogue thereof.

PTPM HUMAN protein-tyrosine phosphatase MU precursor (EC 3.1.3.48) (R-PTP-MU), preferably including amino acids 818- 822, 833- 837; 1082- 1086 having the sequences SVSSP, STSVP, SKSPP or functional equivalents or analogues thereof.

5

PGDS HUMAN alpha platelet-derived growth factor receptor precursor (EC 2.7.1.112), preferably including amino acids 616- 620 having the sequence SRSQP or a functional equivalent or analogue thereof.

- 10 IG1R HUMAN insulin-like growth factor I receptor precursor (EC 2.7.1.112), preferably including amino acids 1311- 1315 having the sequence SSSLP or a functional equivalent or analogue thereof.

- 15 FGR4 HUMAN fibroblast growth factor receptor 4 precursor (FGFR-4) (EC 2.7.1.112), preferably including amino acids 439- 443, 791- 795 having the sequences SSSGP, SSSFP or functional equivalents or analogues thereof.

- 20 FGR2 HUMAN fibroblast growth factor receptor 2 precursor (FGFR-2) (EC 2.7.1.112), preferably including amino acids 780- 784 having the sequence SPSYP or a functional equivalent or analogue thereof.

Q13635 patched protein homolog (PTC), preferably including amino acids 1290- 1294 having the sequence SGSLP or a functional equivalent or analogue thereof.

- 25 MANR HUMAN macrophage mannose receptor precursor, preferably including amino acids 1432- 1436 having the sequence SQSSP or a functional equivalent or analogue thereof.

- 30 LRP2 HUMAN low-density lipoprotein receptor-related protein 2 precursor (megalin), preferably including amino acids 4616- 4620 having the sequence SPSLP or a functional equivalent or analogue thereof.

IDD HUMAN integral membrane protein DGCR2/IDD precursor (KIAA0163), preferably including amino acids 526- 530 having the sequence^{*}SGSTP or a functional equivalent or analogue thereof.

- 5 AMFR HUMAN autocrine motility factor receptor precursor (AMF receptor) (GP78), preferably including amino acids 203- 207 having the sequence SVSPP or a functional equivalent or analogue thereof.

- 10 ACH5 HUMAN neuronal acetylcholine receptor protein, alpha-5 chain precursor, preferably including amino acids 382-386 having the sequence SGSGP or a functional equivalent or analogue thereof.

- 15 In another aspect of the present invention, there is provided a phosphorylated binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a functional equivalent or analogue thereof and wherein at least two (2) of the at least five (5) amino acids are serine and wherein at least one serine residue of the motif is phosphorylated.

- 20 Preferably, the receptor is selected from the group of receptors described above and the amino acid sequence comprising at least five (5) amino acid is any one of the binding motifs described above.

- 25 The motif must have at least two serine residues. Preferably, the second serine residue from the 5' end of the motif is phosphorylated.

- 30 In a further preferred aspect, there is provided a binding motif of a GM-CSF/IL-3/IL-5 receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least ⁵⁸²HSRSLP⁵⁸⁷ of the GM-CSF/IL-3/IL-5 receptor or a functional equivalent or analogue thereof wherein at least Ser⁵⁸⁵ is phosphorylated.

More preferably, the binding motif binds to the cytoplasmic protein 14-3-3.

It is also preferred that other receptors as described above can be phosphorylated and induced to bind a cytoplasmic protein such as 14-3-3 by phosphorylation preferably of the second serine residue from the 5' end of the motif.

In another aspect of the present invention, there is provided a method of phosphorylating a binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence of at least five (5) amino acids, a functional equivalent or analogue thereof and wherein at least two (2) of the at least five (5) amino acids are serine, said method comprising binding a triggering molecule to the receptor.

In a preferred aspect, phosphorylation of the binding motif is caused by the binding of a triggering molecule to its corresponding receptor. Triggering molecules may be cytokines which bind to cytokine receptors. Preferably the receptor is a heterodimeric receptor. More preferably it is a GM-CSF/IL-5/IL-3 receptor bound by a GM-CSF, IL-5 or IL-3 cytokine. Other triggering molecules may be the corresponding triggering molecule that binds to any one of the receptors listed above.

Preferably the binding motif is as described above.

It has been found by the applicants that any triggering molecule which binds to a receptor or receptor signaling system may be capable of causing phosphorylation of the binding motif. Preferably the triggering molecule is a cytokine which binds to a homodimeric or heterodimeric receptor prior to phosphorylation of the binding motif. Preferably the cytokine binds to a heterodimeric cytokine receptor. The heterodimeric cytokine receptor may comprise two (or three) subunits which subserve distinct and specialised functions. These subunits include the major ligand binding subunit (α subunit) and the signaling subunit which may comprise

a β or δ subunit. The signaling subunit may recognise several cytokines on the α subunit which can then transduce signals from the cytokines into the cell.

5 The common beta chain (β_c) is found in the receptor signalling systems of cytokines including granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5). In this system, preferably the binding motif comprises an amino acid sequence of at least ⁵⁸²HSRSLP⁵⁸⁷ on the β_c . More preferably, this sequence is phosphorylated upon binding of GM-CSF, IL-3 or IL-5 to the receptor. More preferably Ser⁵⁸⁵ is phosphorylated.

10

However, other triggering molecules can cause phosphorylation of an equivalent region of the receptor. For instance, the molecule which binds to the receptor (as listed above) may cause phosphorylation to the binding motif.

15 In another aspect of the present invention, there is provided a method of binding a cytoplasmic protein to a receptor, said method comprising:

phosphorylating a binding motif of a receptor as described above, a functional equivalent or analogue thereof; and

20

subjecting the binding motif of the receptor to a cytoplasmic protein.

Although not wishing to be limited by theory, it is perceived that the phosphorylation of the binding motif may improve the binding of a cytoplasmic protein to the binding motif so that when the cytoplasmic protein is reacted with the motif, or equivalent thereof, binding may occur to bring other cytoplasmic proteins or signaling molecules into close proximity to the receptor. Phosphorylation may occur by any means which transfers a phosphoryl (phosphate) group to the cytoplasmic binding motif.

30

The cytoplasmic protein may be 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of

events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival.

In another aspect of the present invention, there is provided a method of
5 activating cellular activities said method including:

phosphorylating a binding motif of a receptor as described above, a functional equivalent or analogue thereof; and

10 subjecting the binding motif to a cytoplasmic protein wherein said cytoplasmic protein is associated with cellular activities.

Preferably the cytoplasmic protein is 14-3-3 protein, or any cytoplasmic protein capable of binding a further signaling molecule which activates a cascade of
15 events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. Preferably the cytoplasmic binding protein is 14-3-3.

The 14-3-3 molecule binds not only to the cytoplasmic binding motif (as found by
20 the applicants) but has the ability to bind to a wide range of signaling molecules and to participate in a number of cell signaling pathways resulting in mitogenesis, transformation, differentiation or cell survival.

Once 14-3-3 or an equivalent binds to the binding motif of the receptor, its
25 ubiquitous nature can bind cytoplasmic proteins involved in signaling pathways which activate these pathways. For instance, not being limited by theory and by example, it has now been found by the Applicants that cytokines such as GM-CSF, IL-3 or IL-5, will bind to the β_c of the receptor. The binding motif of the receptor is then phosphorylated and preferably phosphorylates the ⁵⁸⁵Ser or
30 equivalent residue. 14-3-3 can bind to the phosphorylated motif thereby positioning the 14-3-3 close to the receptor for further binding of cytoplasmic

proteins involved in cell signaling (signaling molecules) for cellular activities such as proliferation, differentiation or even cell survival.

In yet another aspect of the present invention there is provided a method of
5 regulating cellular activities, said method including:

phosphorylating a binding motif of a receptor as described above, a functional equivalent or analogue thereof;

subjecting the binding motif to a cytoplasmic protein to bind the
10 cytoplasmic protein to the binding motif; and

activating a cell signaling pathway by interacting the bound cytoplasmic protein with a signaling molecule involved in the pathway.

Preferably, the cytoplasmic protein is 14-3-3 protein, or any cytoplasmic protein
15 capable of binding a further signaling molecule which activates a cascade of events leading to cell signaling pathways and biological functions such as mitogenesis, proliferation, transformation, differentiation and cell survival. Preferably the cytoplasmic binding protein is 14-3-3.

20 There are many signaling molecules involved in cellular pathways leading to cellular activity. However, it is preferred in the present invention to provide a molecule that binds to a phospho-serine bound 14-3-3 molecule such that a pathway is coupled to the motif or equivalent unit in a receptor and brought into close proximity to downstream signaling proteins at, or near, the cell membrane.
25 Cellular activities may include cell survival, transformation, differentiation and mitogenesis.

For regulating cell survival, it is preferred to activate the PI-3-kinase pathway using a PI-3 kinase bound to a phosphoserine bound 14-3-3. This may be shown
30 in Figure 18.

Phosphorylation of the motif may be conducted by any means which results in phosphorylation of the cytoplasmic binding motif. Preferably, the phosphorylation is induced by a triggering molecule such as a cytokine selected from the group including GM-CSF, IL-3 or IL-5. More preferably for cell survival, it is induced by IL-3. In this case, the β_c is phosphorylated. More preferably the binding motif comprising the amino acid sequence HSRSLP is phosphorylated. More preferably the second serine from the 5' end is phosphorylated. In β_c , the correlates to ⁵⁸⁵Ser.

Regulation of cell survival may include enhancing or reducing cell survival or even causing cell death. This may be achieved by enhancing or inhibiting any of the steps described above.

In another aspect of the present invention, there is provided a method of inhibiting cell survival, said method including inhibiting the binding of a cytoplasmic protein to a binding motif of a receptor as described above.

Preferably the cytoplasmic protein is 14-3-3.

Preferably the receptor is the GM-CSF/IL-5/IL-3 receptor and the triggering molecule is IL-3, although a phosphorylation event which phosphorylates ⁵⁸⁵Ser may also trigger the binding of 14-3-3 to the motif.

For cell survival, it is preferred that the binding motif comprises the amino acid sequence HSRSLP or an equivalent or analogue.

Antagonists may be useful to inhibit cell survival by preventing phosphorylation preferably by preventing serine phosphorylation of the β_c or equivalent or preventing the interaction of a signaling molecule binding to a phosphoserine bound 14-3-3 or equivalent. Prevention of phosphorylation of the β_c or binding motif may be by inhibition of the kinases involved in the phosphorylation or it may include mutation of the binding motif to prevent the cytoplasmic protein such as

14-3-3 from binding and activating cell cycle pathways. Preferably the signaling molecule is a PI-3-kinase involved in the PI-3-kinase pathway which leads to cell survival.

- 5 Antagonists may include antibodies or small peptides directed to the cytoplasmic binding motif so as to prevent attachment of cytoplasmic proteins such as 14-3-3 to a phosphoserine residue or a signaling molecule. Antibodies may be generated in response to any of the binding motifs described above by methods known and available to the skilled addressee.

10

Hence, the antagonists as described may be useful as cancer therapeutics to prevent cell survival of cancer cells or it may be useful for preventing or treating leukaemia such as acute myeloid leukaemia (AML). Other uses of antagonists may be in prevention and treatment of inflammatory diseases

15

Applicants have also found that the ⁵⁸⁵Ser in β_c of acute myeloid leukaemia (AML) is constitutively phosphorylated (see Figure 19). Hence by preventing phosphorylation of the ⁵⁸⁵Ser, it may be possible to prevent further binding of 14-3-3 to the binding motif of β_c and further preventing the binding of PI-3-kinase which interacts with the PI-3-kinase pathway to activate cell survival.

20

Accordingly this method of interaction may be a useful tool for a method of treating or preventing cell proliferative diseases such as AML or cancer.

- 25 Targeting may be by way of the use of antagonists as described above or by any means that prevents activation of cell cycles via the binding motif described in the present invention. Targeting may be by blocking or mutating the motif.

Techniques such as gene therapy may also be employed which targets or removes the binding motif.

30

The present invention will now be more fully described with reference to the following examples. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.

5

EXAMPLE 1

BINDING OF 14-3-3 TO A COMMON BETA CHAIN (β_c)

(a) **Mutagenesis of human β_c and expression plasmid constructs.**

Substitution mutations of two sequences within the cytoplasmic domain of the human β_c cDNA were constructed using oligonucleotide-directed mutagenesis (Altered-sites, Promega, Sydney, NSW, Australia) as described in Wood Cock, J.M. et al (1994) EMBO, 13, 5176. Both mutants were essentially poly-alanine substitutions. Mutagenesis oligonucleotides encoding non-alanine residues were included to facilitate restriction enzyme screening of mutant clones. The first motif was ⁵⁸²HSRSLP⁵⁸⁷ mutated to ⁵⁸²EFAAAA⁵⁸⁷, and the second was ⁸²⁰RSKPSSP⁸²⁶ mutated to ⁸²⁰EFAAAAAA⁸²⁶. The point mutant S585A was also constructed, however this mutant created a cryptic proteolytic site in β_c and was not able to be used. The mutations were confirmed by nucleotide sequencing and the mutant β_c cDNAs subcloned into the eukaryotic expression vector *pcDNA1* (Invitrogen, San Diego, CA). The β_c deletion mutant cDNAs were a kind gift of Dr A. Miyajima.

(b) **GM-CSF and IL-3.** Recombinant human IL-3 and GM-CSF were produced in *E.coli* essentially as described in Barry, S.C. et al (1994) J. Biol chem, 269, 8488 and Hercus, T.R. et al (1994) Proc. Natl. Acad. Sci., 91, 5838. Cytokine purity and quantitation was determined by HPLC analysis and Coomassie staining of SDS-PAGE separated proteins. The activity of the cytokines based on the ED₅₀ values in a TF-1 proliferation assay (Kitamura, T. et al (1989) J. Cell Physiol, 140, 323) was 0.03ng/ml for GM-CSF and 0.1ng/ml for IL-3.

30

(c) **Antibodies.** The monoclonal antibodies 8E4 and 1C1 directed against the β_c were generated as previously described in Stomski, F.C. et al (1998) J. Biol.

Chem., 273, 1192. The anti-phospho-⁵⁸⁵Ser β_c antibody was raised by immunising New Zealand white rabbits with the phosphorylated CLGPPHSRSLPDILG peptide conjugated to keyhole limpet hemocyanin (Sigma). The anti-peptide antibody was firstly affinity purified with the immunising peptide
 5 conjugated to sepharose and then absorbed with the nonphosphorylated CLGPPHSRSLPDILG peptide conjugated to sepharose. The specificity of the anti-phospho-⁵⁸⁵Ser β_c antibody was verified by dot immunoblots against the CLGPPHSRSLPDILG peptide either non phosphorylated or serine phosphorylated form and a scrambled peptide LPLSGPDSHIRGPL. The
 10 corresponding phosphorylated serine in each peptide is underlined. Peptides were synthesised by Chiron Mimotopes, Melbourne, Australia. The anti-14-3-3z antibody was kindly provided by Dr A. Aitken.

(d) **Cell culture and DNA transfection.** The HEK293T cell line was
 15 maintained in RPMI-1640 supplemented with 10 % v/v fetal calf serum (FCS). On the day before transfection, 1.4×10^6 cells were plated into 6 cm tissue culture dishes to adhere overnight. Four hours after a medium change, 6 mg of wild type or mutated β_c cDNA was added to cells in the form of a calcium phosphate precipitate (Graham, F.L. et al (1973) Virology, 52, 456), and the cells were
 20 placed in an incubator for 4-6 h to permit the uptake of the DNA-calcium phosphate precipitate. The cells were then washed, replated and placed in the incubator for 48h prior to cytokine treatment. M1 cell line expressing GM-CSF receptor alpha chain and β_c wild type was maintained in RPMI-1640 supplemented with 10 % v/v FCS. The M1 cell line was kindly provided by Dr N.
 25 Nicola.

(e) **Surface marker analysis by flow cytometry.** Expression of receptors on transfected cells was verified by flow cytometry. Briefly, cells were incubated with the anti- β_c MAb (1C1) (Stomski, F.C. et al (1996) Mol. Cell. Biol, 16, 3035) or anti-
 30 GM-CSFRa MAb (4H1) (Stomski, F.C. et al (1998) J. Biol. Chem. 273, 1192) for 20 minutes on ice, washed, and subsequently incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG antibody (Silenus Laboratories,

Hawthorn, Victoria, Australia) for 20 minutes on ice. Cells were then washed and resuspended in FACS FIX and analysed using a Profile II (Coulter Electronics).

(f) **Immunoprecipitations.** Cells were lysed in lysis buffer [150mM NaCl, 10mM Tris-HCl (pH 7.4), 1% Digitonin with protease inhibitors (10mg/ml leupeptin, 2mM phenylmethanesulfonyl fluoride, 10mg/ml aprotinin) and 2mM sodium vanadate] for 30 mins at 4°C followed by centrifugation of the lysate for 15 mins at 12,000g at 4°C. Following a 1 hour preclearance with Protein-A-sepharose (Pierce, Rockford, IL) at 4°C, the supernatant was incubated for 2 hours with 5mg/ml antibody. Protein-immunoglobulin complexes were captured by incubation for 1 hour with Protein-A-sepharose followed by 6 subsequent washes in lysis buffer. Samples were boiled for 5 mins in SDS sample load buffer in the presence or absence of 2-mercaptoethanol before separating immunoprecipitated proteins by SDS-PAGE.

15

(g) **Precipitations.** Cells were lysed in lysis buffer for 30 mins at 4°C followed by centrifugation of the lysate for 15 mins at 12,000g 4°C. Following a 1 hour preclearance with GST-sepharose at 4°C, the supernatant was incubated for 2 hours with GST-14-3-3-sepharose followed by 3 subsequent washes in lysis buffer. Samples were boiled for 5 mins in SDS sample load buffer in the presence of 2-mercaptoethanol before separating precipitated proteins by SDS-PAGE.

(h) **Competition of precipitations and immunoprecipitations by peptides.** Cell lysates were precipitated or immunoprecipitated in the presence of various concentrations of the following peptides: β_c peptide sequence CLGPPHSRSLPDILG either non phosphorylated or serine phosphorylated and a scrambled peptide CLPLSGPDSHIRGPL. Raf1 peptides corresponding to the sequence CLSQRQRSTSTPNVHM were also used and were either non phosphorylated or serine phosphorylated. The corresponding phosphorylated serine in each peptide is underlined. Peptides were synthesised by Chiron Mimotopes, Melbourne, Australia. The presence of β_c in either the

30

immunoprecipitation or precipitation experiment was determined by Western blotting with anti- β_c antibody (MAb 1C1).

(i) **SDS-Polyacrylamide Gel Electrophoresis, Immunoblot and ECL**

5 Immunoprecipitated proteins separated by SDS-PAGE were transferred to nitrocellulose membrane by electroblotting. Dot blots of peptides were performed by spotting either 10 or 100 ng of each peptide onto nitrocellulose membranes. Routinely, nitrocellulose membranes were blocked in a solution of PBS/0.05% (v/v) Tween 20 (PBT) containing 1% (w/v) blocking reagent 1096 176 (Boehringer
10 Mannheim) and probed with anti- β_c (1C1), anti-14-3-3z³³ or anti-phospho-⁵⁸⁵Ser β_c followed by either anti-mouse or rabbit peroxidase conjugated antibodies. Immunoreactive proteins were detected by chemiluminescence using the ECL kit (Amersham, Little Chalfont, U.K.) following the manufacturer's instructions.

15

(j) **Binding of the ¹²⁵I-labeled 14-3-3z to Synthetic Peptides.** The recombinant 14-3-3z protein was ¹²⁵I-labeled using IODOBEADS (Pierce). The synthetic peptides were solubilised in distilled water and then diluted to 50mg/ml in 0.1 M NaHCO₃, pH 9.2. The peptides were coated onto microtiter wells
20 (Immunolon II Removawells, Dynatech Laboratories, Chantilly, VA) by incubation at 22°C for 6 h and then 4°C overnight. The peptide coated microtiter wells were blocked at 22°C with 5% bovine serum albumin for 2h and then with ¹²⁵I-labeled 14-3-3z protein for 2h. After three washes, microtiter well-bound radioactivity were estimated in a g-counter.

25

The results of these experiments show that that firstly, β_c interacts with 14-3-3, and secondly, that the region of interaction lies between amino acids 544 and 626.

30

EXAMPLE 2

BINDING OF 14-3-3 TO ⁵⁸²HSRSLP⁵⁸⁷ MOTIF OF β_c

We then examined whether 14-3-3 interacted with β_c via the $^{582}\text{HSRSLP}^{587}$ motif which lies within the 544-626 region identified in Figure 5. A substitution mutant (β_c - $^{582}\text{HSRSLP}^{587}\rightarrow\text{EFAAAA}$) and a point mutant (β_c -585S \rightarrow A) in the putative 14-3-3 binding site were constructed as well as a control mutant (β_c - $^{820}\text{RSKPSSP}^{826}\rightarrow\text{EFAAAA}$). These mutants were expressed in HEK 293T cells and examined for their ability to interact with GST-14-3-3 in pull-down experiments. While wild type β_c and the control mutant β_c interacted with GST-14-3-3, no detectable interaction was observed for the β_c - $^{582}\text{HSRSLP}^{587}\rightarrow\text{EFAAAA}$ mutant (Figure 6). These results indicate that 14-3-3 associates with β_c via the $^{582}\text{HSRSLP}^{585}$ sequence.

EXAMPLE 3

ROLE OF ^{585}Ser IN β_c INTERACTION WITH 14-3-3

14-3-3 is known to be a phospho-serine binding protein which interacts with the RSXSXP motif, where S is phosphorylated. We tested whether ^{585}Ser phosphorylation within the $^{582}\text{HSRSLP}^{587}$ motif would be required for 14-3-3 association. We synthesised a β_c peptide containing a non-phosphorylated ^{585}Ser (C $^{578}\text{LGPPHSRSLPDILG}^{591}$) and a β_c peptide containing a phosphorylated ^{585}Ser and examined their ability to inhibit β_c interaction with GST-14-3-3 in a pull-down experiment. While the peptide containing phosphorylated ^{585}Ser inhibited β_c association with GST-14-3-3, no inhibition of association was observed for the peptide containing the non-phosphorylated ^{585}Ser (Figure 4). As a comparison, nonphosphorylated and phosphorylated peptides corresponding to the 14-3-3 binding site in Raf-1 were also tested. We found that the serine phosphorylated Raf-1 peptide was also able to inhibit β_c association with 14-3-3 while the non-phosphorylated peptide did not (Figure 4). Furthermore, the ability of the β_c phosphorylated peptide to inhibit the association of β_c with 14-3-3 was dose-dependent and specific as another phosphorylated peptide with sequence corresponding to a different region of β_c failed to inhibit this association (Figure 8). Direct binding experiments and Scatchard analysis demonstrated that the phosphorylated peptide (C $^{578}\text{LGPPHSRSLPDILG}^{591}$) bound to 14-3-3 with an affinity of approximately 150nM (Figure 9). These experiments show that the

⁵⁸²HSRSLP⁵⁸⁷ sequence in β_C directly binds to 14-3-3 and that this binding is dependent on ⁵⁸⁵Ser being phosphorylated.

EXAMPLE 4 - IN VIVO REGULATION OF ⁵⁸⁵SER PHOSPHORYLATION

5 Having identified the requirement for β_C ⁵⁸⁵Ser to be phosphorylated to allow 14-3-3 binding, we then examined whether ⁵⁸⁵Ser was phosphorylated *in vivo* and whether its phosphorylation was regulated by GM-CSF. These possibilities were initially addressed using ³²P-orthophosphate labelled HEK 293T cells transfected with the GM-CSF receptor (α and β_C subunits). These cells were stimulated with

10 GM-CSF, total β_C was immunoprecipitated and examined for ³²P-labelling. This is most likely due to the presence of sixty serine and threonine residues in the intracellular region of β_C , some of which may be constitutively phosphorylated. In order to directly address the phosphorylation status of β_C ⁵⁸⁵Ser *in vivo*, we raised a rabbit antiserum against a peptide containing the 14-3-3 binding site identified

15 in β_C : C⁵⁷⁸LGPPHSRSLPDILG⁵⁹¹. This antibody preparation, termed anti-phospho-⁵⁸⁵Ser specifically recognised the CLGPPHSRSLPDILG peptide containing a phosphorylated ⁵⁸⁵Ser but not a peptide containing a non-phosphorylated ⁵⁸⁵Ser or a peptide containing a scrambled 14-3-3 binding site (Figure 10). The specificity of the anti-phospho-⁵⁸⁵Ser antibody was further

20 confirmed by Western blotting of immunoprecipitated β_C from GM-CSF receptor-transfected HEK 293T cells. In these experiments, the phosphorylated CLPPHSRSLPDILG peptide was able to inhibit anti-phospho-⁵⁸⁵Ser recognition of β_C , while the non-phosphorylated and scrambled peptides did not (Figure 10b). In addition, pretreatment of β_C immunoprecipitates with calf intestinal phosphatase

25 prior to Western blot analysis completely abolished the anti-phospho-⁵⁸⁵Ser signal and immunoprecipitation of either the wild type β_C or the ⁵⁸²HSRSLP⁵⁸⁷→EFAAAA mutant from HEK293T transfected cells followed by western blot analysis with the anti-phospho-⁵⁸⁵Ser antibody demonstrated that this antibody specifically recognised the wild type but not the mutant receptor

30 (data not shown).

Using these anti-phospho-⁵⁸⁵Ser specific antibodies we then examined the regulation of β_C ⁵⁸⁵Ser phosphorylation following GM-CSF stimulation of M1 myeloid leukaemic cells. M1 myeloid leukaemic cells were stimulated with 2 ng/ml GM-CSF, β_C was immunoprecipitated, and immunoprecipitates probed with the anti-phospho-⁵⁸⁵Ser antibody. As shown in Figure 10, GM-CSF stimulation strongly upregulated ⁵⁸⁵Ser phosphorylation of β_C .

EXAMPLE 5

IL-3 INDUCES Ser585 PHOSPHORYLATION OF β_C AND RECRUITMENT OF 14-3-3.

We have described the biochemical interaction of the β_C of the GM-CSF, IL-3 and IL-5 receptors with the 14-3-3 family of phospho-serine binding proteins. These studies identified a motif, ⁵⁸²HSRSLP⁵⁸⁷, in the cytoplasmic domain of β_C that binds 14-3-3 when Ser585 is phosphorylated. To address the functional significance of 14-3-3 binding to β_C we generated cell lines expressing either wild type or mutant IL-3 receptors lacking the 14-3-3 binding site. CTL-EN cells were transduced with viral constructs expressing IL-3Ra and either wt β_C , a substitution mutant that encompasses the 14-3-3 binding site (β_C HSRSLPmEFAAAA) or a point mutant in which Ser585 of the 14-3-3 binding motif was substituted for alanine (β_C S585A). The β_C S585A point was not able to be used in these studies as it appeared to introduce a cryptic proteolytic cleavage site. Western blot analysis and flow cytometry indicated that this mutant was proteolysed and failed to be expressed on the cell surface (Stomski et al., 1999). Similar expression levels of wt β_C and β_C HSRSLPmEFAAAA were observed in the CTL-EN cells by both flow cytometry (data not shown) and Western blot analysis (see below). Similar expression levels of IL-3Ra were also observed for each cell line.

The regulation of β_C Ser585 phosphorylation in response to IL-3 stimulation was then examined in these cell lines using anti-phospho-Ser585 β_C antibodies. These antibodies have been shown to specifically recognize the phosphorylated 14-3-3 binding motif HSRSLP (where S is phosphorylated) but not the non-

phosphorylated motif. CTL-EN cells expressing wt β_C or β_C HSRSLPmEFAAAA were starved for 4 hours in 0.1% FCS and then stimulated with 50ng/ml of IL-3. The β_C was immunoprecipitated and then subjected to immunoblot analysis using the anti-phospho-Ser585 β_C antibodies. Ser585 phosphorylation was upregulated

5 in response to IL-3 stimulation in CTL-EN cells expressing wt while no signal was detected for the β_C HSRSLPmEFAAAA mutant control (Fig. 11a). Tyrosine phosphorylation of β_C was detected for both the wt β_C and the β_C HSRSLPmEFAAAA mutant (Fig. 11a). Co-immunoprecipitation experiments showed that increased β_C Ser585 phosphorylation in response to IL-3 stimulation

10 also resulted in increased 14-3-3 binding to β_C (Fig. 11b). No association of 14-3-3 with the β_C HSRSLPmEFAAAA mutant control in response to IL-3.

EXAMPLE 6

15 **cAMP-DEPENDENT PROTEIN KINASE (PKA) PHOSPHORYLATES Ser585 OF**

In an effort to identify the kinase involved in the phosphorylation of Ser585, we firstly examined the ability of several kinases to phosphorylate the purified recombinant intracellular portion of β_C (his β_C 445-881) *in vitro*. Ser585 of β_C lies within a SXXD motif which is known to be a CKII consensus phosphorylation site.

20 Ser585 also lies within a RS motif which is a possible, but poor, PKA phosphorylation site. In the *in vitro* kinase assay shown in Figure 12a, 32 P-labelling of his β_C 445-881 was observed for both PKA and CKII. Additional bands for the PKA kinase reactions were evident due to the autocatalytic activity of PKA. Interestingly, the presence of a non-phospho-HSRSLP peptide reduced the

25 phosphorylation of his β_C 445-881 by PKA whereas a phospho-HSRSLP or a scrambled peptide did not (Fig. 12a). In this experiment, the non-phospho-HSRSLP peptide is likely to act as a competitive substrate for phosphorylation of Ser585 of his β_C 445-881 by PKA. The phospho-HSRSLP and scrambled peptides would not act as competitive substrates and therefore did not result in decreased

30 phosphorylation of his β_C 445-881. On the other hand, the phosphorylation of

his β_C 445-881 by CKII was not inhibited by any of the peptides suggesting that CKII cannot phosphorylate Ser585 of his β_C 445-881 (Fig. 12a).

To further examine the possibility that PKA could phosphorylate Ser585 of β_C , we performed *in vitro* kinase assays using cold ATP and examined the phosphorylation of Ser585 by immunoblot analysis using the anti-phospho-Ser585 β_C antibodies. CKII was not able to detectably phosphorylate Ser585 of his β_C 445-881 whereas PKA resulted in strong phosphorylation of Ser585 as detected by the anti-phospho-Ser585 antibody (Fig. 12b). The results shown in Figure 12a and 12b support the proposal that PKA can phosphorylate Ser585 of β_C *in vitro*. We then examined the ability of PKA to phosphorylate Ser585 of β_C *in vivo*. CTL-EN cells expressing wt β_C were starved for 12 hours in DMEM containing 0.5% FCS and then either left unstimulated (nil), stimulated with 50ng/ml IL-3, 50mM forskolin or 100m dibutyryl cAMP for 10 minutes. Cells were lysed, β_C was immunoprecipitated and subjected to immunoblot analysis with the anti-phospho-Ser585 antibody. IL-3 stimulation resulted in increased Ser585 phosphorylation (Fig. 12c, IL-3). In addition, agents that elevate intracellular levels of cAMP and activate PKA were also found to result in increased Ser585 phosphorylation of β_C . Together, the results shown in Figure 12 would suggest that PKA is likely to phosphorylate Ser585 of β_C in response to IL-3 stimulation.

EXAMPLE 7

14-3-3 RECRUITMENT TO β_C IN RESPONSE TO IL-3 IS IMPORTANT FOR THE ACTIVATION OF THE PI 3-KINASE PATHWAY.

The regulation of Ser585 phosphorylation and the recruitment of the phosphoserine adaptor protein 14-3-3 to β_C raised the possibility that these events were important in regulating IL-3 signalling. GM-CSF and IL-3 are known to activate at least three pathways; the JAK/STAT pathway, the ras/MAP kinase pathway and the PI 3-kinase pathway (Guthridge et al., 1998 skin cells 16, 301-313). These pathways are not necessarily mutually exclusive and may have substantial overlap. The PI 3-kinase pathway has been implicated as having an important role in regulating cellular survival in a number of systems (Marte and Downward,

(1997); Trends Biochem Sci 22, 355-358 cell, 88, 435-437) Franke et al., 1997) and, significantly, has been shown to bind 14-3-3 (Bonnefoy-Berard et al., (1995); Lui et al., 1996). We therefore examined the possibility that Ser585 of β_C and 14-3-3 maybe important in the regulation of the PI 3-kinase pathway. CTL-EN cells
 5 expressing wt β_C , or β_C HSRSLPmEFAAAA were starved and stimulated with IL-3, tyrosine phosphorylated proteins were immunoprecipitated and the PI 3-kinase activity of the immunoprecipitates was determined in an *in vitro* kinase assay using phosphatidyl inositol and $g^{32}P$ -ATP as substrates. While IL-3 stimulation of cells expressing wt β_C resulted in the rapid and transient activation of PI 3-kinase
 10 activity, no PI 3-kinase activity was observed in response to IL-3 stimulation for the β_C HSRSLPmEFAAAA mutant indicating that 14-3-3 binding to is necessary for PI 3-kinase activation (Fig. 13a).

Although β_C does not contain a classical YXXM consensus for the direct binding
 15 of PI 3-kinase, our results raise the possibility of an alternative mechanism whereby 14-3-3 could act as an adaptor to recruit PI 3-kinase to β_C via phospho-Ser585. To examine this possibility we performed co-immunoprecipitation experiments examining the association of β_C with the p85 regulatory subunit of PI 3-kinase. CTL-EN cells expressing wt β_C or β_C HSRSLPmEFAAAA were
 20 stimulated with IL-3 for up to 30 minutes, β_C was immunoprecipitated and the immunoprecipitates were examined for associated p85 subunit by immunoblot analysis. IL-3 stimulation resulted in the association of p85 with wt β_C which was maximal at 5 minutes and was decreased by 30 minutes (Fig. 13b). In contrast, the recruitment of p85 to the β_C HSRSLPmEFAAAA mutant in response to IL-3
 25 was virtually abolished (Fig. 13b). We also examined the ability of the mutant β_C to recruit the protein tyrosine phosphatase, SHP2. Previous studies have shown that Tyr612, which lies adjacent to the 14-3-3 binding site, is a likely binding site for SHP2 (Sakamaki K et al., 1992; Bone et al., 1997). Both the wt β_C and the β_C HSRSLPmEFAAAA mutant receptors were able to recruit SHP2 in response to
 30 IL-3 indicating that the 14-3-3 binding mutant did not induce structural alterations that prevented the recruitment of other signalling molecules. These results

suggest that 14-3-3 interaction with β_C is necessary for the recruitment of PI 3-kinase.

The interaction of β_C with PI 3-kinase was further addressed by examining the ability of the p85 subunit of PI 3-kinase to interact with purified his-tagged intracellular-portion of β_C (his β_C 445-881) via the phosphorylated HSRSLP motif. his β_C 445-881 expressed in bacteria is not phosphorylated on Ser585, however as shown in Figure 12a and 12b, we have found that cAMP-dependent protein kinase (PKA) can efficiently phosphorylate Ser585 of his β_C 445-881 *in vitro*. his β_C 445-881 coupled to Sepharose and phosphorylated on Ser585 by PKA was incubated with COS-7 cell lysates and examined for its ability to pull-down p85 by immunoblot analysis. In addition, a number of peptides encompassing the 14-3-3 binding site in β_C (listed in Fig. 3c) were examined for their ability to competitively inhibit the interaction of his β_C 445-881 with p85 (Fig. 12c). his β_C 445-881 Sepharose was able to pull down p85 from the COS-7 cell extracts (Fig. 13d, lane 1) and the presence of scrambled (Fig. 13d, lane 2), Ser585Ala (Fig. 13d, lane 3), or non-phosphorylated-Ser585 (Fig. 31d, lane 4) control peptides had no apparent effect on this interaction. On the other hand, the interaction of p85 with his β_C 445-881 was markedly reduced in the presence of a phospho-Ser585 peptide (Fig. 13d, lane 5). Because the recombinant his β_C 445-881 is not tyrosine phosphorylated and that only a phospho-Ser585 peptide could compete for p85 binding to β_C , these results suggest that Ser585 phosphorylation of β_C is responsible for the association of both 14-3-3 and p85.

To further examine if 14-3-3 binding to β_C was involved in regulating other signalling pathways besides the PI 3-kinase pathway, we investigated a number of additional signalling molecules known to be activated in response to IL-3. CTL-EN cells expressing either wt β_C or the β_C HSRSLPmEFAAAA receptors were starved and then stimulated with IL-3 and the activation of Akt (or protein kinase B), the signal transducer and activator of transcription protein STAT5, and the extracellular-regulated kinases ERK1 and ERK 2 (or MAP kinase) was examined in whole cell lysates by Western blot using phospho-specific antibodies. Akt is a

known downstream target of PI 3-kinase whereas STAT5 and ERK are thought to be regulated by pathways distinct from the PI 3-kinase pathway. CTL-EN cells expressing wt β_C or the β_C HSRSLPmEFAAAA mutant induced STAT5 and ERK phosphorylation in response to IL-3 (Fig. 14a). While CTL-EN cells expressing wt β_C demonstrated phosphorylation of Akt in response to IL-3, the phosphorylation of Akt was almost completely abolished in cells expressing the β_C HSRSLPmEFAAAA mutant (Fig. 14a). The activation of c-jun N-terminal kinase (JNK) was also examined in JNK immunoprecipitates using an *in vitro* kinase assay and GST-jun as a substrate. CTL-EN cells expressing either wt β_C or β_C HSRSLPmEFAAAA were able to induce JNK activity in response to IL-3 (Fig. 14b). Together, these results show that phosphorylation of Ser585 of β_C and 14-3-3 association are important for the recruitment of PI 3-kinase to β_C as well as the activation of its downstream signalling partner Akt. Furthermore, Ser585 phosphorylation of β_C and 14-3-3 binding are important for the specific regulation of the PI 3-kinase pathway but not for the regulation of other known pathways emanating from β_C that utilize STAT5, ERK or JNK.

EXAMPLE 8

ASSOCIATION OF 14-3-3 WITH β_C IS IMPORTANT FOR IL-3-MEDIATED CELL SURVIVAL BUT NOT PROLIFERATION.

Given that 14-3-3 binding to Ser585 of β_C is required for PI 3-kinase activation in response to IL-3 and also the important role PI 3-kinase is thought to play in mediating survival signals, we then examined the ability of IL-3 to promote long-term survival in CTL-EN cells expressing the β_C HSRSLPmEFAAAA mutant receptor. Initial experiments performed in the presence of 10% FCS showed no defect in either the survival or growth of CTL-EN cells expressing the β_C HSRSLPmEFAAAA mutant receptor (data not shown). However, a clear defect in the survival of CTL-EN cells expressing the β_C HSRSLPmEFAAAA mutant was observed under low serum conditions. CTL-EN cells expressing the

wt IL-3 receptor remain greater than 90% viable for up to 3-4 days under low serum conditions (0.1% FCS) in the presence of IL-3. To test the ability of IL-3 to promote cell survival, CTL-EN cells expressing either wt β_C or β_C HSRSLPmEFAAAA were plated out at 2.5×10^5 cells/ml in the presence of IL-3 or IL-2 in medium containing 0.1% FCS and viable cells were counted after 4 days. While CTL-EN cells expressing wt β_C remained greater than 90% viable for up to 3-4 days in the presence of either IL-3 or IL-2, cells expressing the β_C HSRSLPmEFAAAA mutant showed a loss of viability in the presence of IL-3 with only 7% viable cells remaining after 4 days (Fig 15a). Cells expressing the mutant receptor were able to maintain viability in the presence of IL-2. Importantly, CTL-EN cells expressing the wt β_C lost viability in the presence of IL-3 and the PI 3-kinase inhibitor, LY294002, confirming that PI 3-kinase activity is essential for the survival these cells (Fig. 5a). As the defect in survival was apparent under low serum conditions (0.1% FCS) but not in the presence of 10% FCS, these results would suggest that there are factors in serum that can, at least in part, activate survival signals similar to those induced by IL-3. In fact, we have found that while serum is neither necessary for the promotion of CTL-EN cell survival (IL-3 in serum-free medium can promote survival of CTL-EN cells expressing the IL-3 receptor) nor sufficient in promoting survival (10% FCS fails to promote survival of CTL-EN cells expressing the IL-3 receptor) it can clearly augment the ability of IL-3 to stimulate cell survival (unpublished observations and these studies).

Loss of cell viability in CTL-EN cells expressing the β_C HSRSLPmEFAAAA in response to IL-3 was also reflected in loss of cellular metabolic activity as determined by the MTS reduction assay. CTL-EN cells expressing wt β_C maintain appreciable levels of metabolic activity in the presence of IL-3 and 0.1% FCS for up to 3 days but lost metabolic activity in the absence of hIL-3 (Fig. 15b). CTL-EN cells expressing the β_C HSRSLPmEFAAAA mutant receptor lost metabolic activity in the presence of IL-3 (Fig. 15b). These data further suggest that the association of 14-3-3 with β_C in response to IL-3 is important for maintaining cellular viability.

To determine if the signalling defect of the β_c HSRSLPmEFAAAA receptor was specifically related to cell survival or if cell proliferation was also impaired, cell cycle progression in response to IL-3 was examined. CTL-EN cells were starved in medium containing 0.1% FCS and no IL-3 for 24 hours and then stimulated with IL-3 for up to 24 hours. The cells were then fixed in ethanol and the cell cycle distribution was examined by prodidium iodide staining and flow cytometry. Under these starvation conditions, nearly 90% of CTL-EN cells accumulate in the G_0/G_1 phase of the cell cycle (Fig. 16a). CTL-EN cells expressing either wt β_c or the β_c HSRSLPmEFAAAA mutant and synchronized in G_0/G_1 were both able to re-enter the cell cycle in response to IL-3 indicating that Ser585 phosphorylation, and 14-3-3 binding are not essential for signals that promote cell cycle progression (Fig. 16a). We also examined the regulation of c-myc mRNA expression in response to IL-3 by Northern blot analysis. The induction of c-myc is proposed to be an important pre-requisite for cell proliferation. No impairment of c-myc mRNA induction was observed in CTL-EN cells expressing β_c HSRSLPmEFAAAA when compared to control cells expressing wt β_c (Fig. 16b).

EXAMPLE 9

LOSS OF 14-3-3 BINDING TO β_c RESULTS IN CELL DEATH BY APOPTOSIS.


We then performed Annexin V binding studies to determine if the loss in cell viability in CTL-EN cells expressing the β_c HSRSLPmEFAAAA mutant was due to apoptosis. CTL-EN cells expressing wt β_c or β_c HSRSLPmEFAAAA were washed and placed in medium containing 0.1% FCS and either IL-2 or IL-3 for 16 hours. The cells were then stained with annexin V and apoptotic cells were analysed by flow cytometry. CTL-EN cells expressing wt β_c or β_c HSRSLPmEFAAAA showed negligible annexin V staining in the presence of IL-2 (Fig. 17). However, in the presence of IL-3, CTL-EN cells expressing the β_c HSRSLPmEFAAAA mutant showed increased annexin V staining compared to cells expressing the wt β_c indicating that the defect in cell survival is due to increased apoptosis (Fig. 17).

Finally it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

5 DATED: 15 September, 1999

PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

A handwritten signature in black ink, reading "David B Fitzpatrick". The signature is written in a cursive style with a large, stylized 'D' and 'F'.

MEDVET SCIENCE PTY LTD

Figure 1

MVLAQGLLSM	ALLALCWERS	LAGAETIPL	QTLRCYNDYT	SHITCRWADT
QDAQRLVNVY	LIRRVNEDLL	EPVSCDLSDD	MPWSACPHPR	CVPRRCVIPC
QSFVVTDDY	FSFQDRPLG	TRLTVTLTQH	VQPPEPRDLQ	ISTDQDHFL
TWSVALGSPQ	SHWLSPGDLE	FEVVYKRLQD	SWEDAAILLS	NTSQATLGPE
HLMPSSSTYVA	RVRTRLAPGS	RLSCRPSKWS	PEVCWDSQPG	DEAQPNLEC
FFDGAAVLSC	SWEVRKEVAS	SVSFGLFYKP	SPDAGEEECS	FVLREGLGSL
HTRHHQCIPV	PDPATHQYI	VSVQPRRAEK	HIKSSVNIQM	APPSLNVTKD
GDSYSLRWET	MMRYEHIDH	TTFIQYRKDT	ATWKDSKTET	LQNAHSMALP
ALEPSTRYWA	RVRVRTSRTG	YNGIWESE	ARSWDTESVL	PMWVLALIVI
FLTIALLAL	RFCGIYGYRL	RRKWEKIPN	PSKSHLFQNG	SAELWPPGSM
SAFTSGSPPH	QGPWGSRPPE	LEGVFPVGFQ	DSEVSPLTIE	DPKHVCDPPS
QPDITPAASD	LPTEQPPSPQ	PGPPAASHTP	EKQASSFDFN	GPYLQPPHER
SLPDILQQPE	PPQEGGSQKS	PPPGSLEYLC	LPAGGQVQLV	PLAQAMGPGQ
AVEVERRPSC	GAAGSPSLES	GGGPAPPALG	PRVGGQDQKD	SPVAIPMSSG
DTEDPGVASG	YVSSADLVFT	PNSGASSVSL	VPSLGLPSDQ	TPSLCPGLAS
GPPGAAPGVK	SGFEGYVELP	PIEGRSPRSP	RNNFVPPEAK	SPVLNPGERP
ADVSPSTSPQ	EGLLVLQQVG	DYCFLLPQLQ	GPLSLRSKPS	SPGPGPETKN
LDQAFQVKKP	PGQAVPQVPV	IQLFKALKQQ	DYLSLPPWEV	NKPGEVC

Figure 2

KKIT_HUMAN: STEM CELL GROWTH FACTOR RECEPTOR
(PROTO-ONCOGENE TYROSINE-PROTEIN KINASE KIT) (C-KIT) (CD117 ANTIGEN).
SEQUENCE 976 AA; 109864 MW;

```
MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD
PGFVKWTFEI LDETNNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV
DRSLYGKEDN DTLVRCPLTD PEVTNYSKLG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH
RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS
SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN
VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE
DYPKSENESEN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR
LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV
MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF
GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC
TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE
YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM
AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPEP
IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY
DIMKTCWDAD PLKRPTFKQI VOLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV
GSTASSSQPL LVHDDV
```

Figure 3

TPOR_HUMAN: THROMBOPOIETIN RECEPTOR PRECURSOR (TPO-R)
(MYELOPROLIFERATIVE LEUKEMIA PROTEIN) (C-MPL).

TPOR OR MPL.

635 AA; 71244 MW

```
MPSWALFMVT  SCLLLAPQNL  AQVSSQDVSL  LASDSEPLKC  FSRTFEDLTC  FWDEEEAAPS
GTYQLLYAYP  REKPRACPLS  SQSMPHFGTR  YVCQFPDQEE  VRLFFPLHLW  VKNVFLNQTR
TQRVLFVDSV  GLPAPPSIIK  AMGGSQPGEL  QISWEEPAPPE  ISDFLRYELR  YGPRDPKNST
GPTVIQLIAT  ETCCPALQRP  HSASALDQSP  CAQPTMPWQD  GPKQTSPSRE  ASALTAEGGS
CLISGLQPGN  SYWLQLRSEP  DGISLGGSWG  SWSLPVTVDL  PGDAVALGLQ  CFTLDLKNVT
CQWQQQDHAS  SQGFFYHSRA  RCCPRDRYPI  WENCEEEEEKT  NPGLQTPQFS  RCHFCKSRNDS
IIHILVEVTT  APGTVHSYLG  SPFWIHQAVR  LPTPNLHWRE  ISSGHLELEW  QHPSSWAAQE
TCYQLRYTGE  GHQDWKVLEP  PLGARGGTLE  LRPRSRYRLQ  LRARLNGPTY  QGPWSSWSDP
TRVETATETA  WISLVTALHL  VLGLSAVLGL  LLLRWQFFAH  YRRLRHALWP  SLPDLHRVLG
QYLRDTAALS  PPKATVSDTC  EEVEPSLLEI  LPKSSERTPL  PLCSSQAQMD  YRRLQPSCLG
TMPLSVCPPM  AESGSCCTTH  IANHSYLPLS  YWQQP
```

Figure 4

TPOR_MOUSE: THROMBOPOIETIN RECEPTOR PRECURSOR (TPO-R)
(MYELOPROLIFERATIVE LEUKEMIA PROTEIN) (C-MPL).
TPOR OR MPL.
625 AA; 69817 MW;

MPSWALFMVT SCLLLALPNQ AQVTSQDVFL LALGTEPLNC FSQTFEDLTC FWDEEEAAPS
GTYQLLYAYR GEKPRACPLY SQSVPTFGTR YVCQFPAQDE VRLFFPLHLW VKNVSLNQT
IQRVLFVDSV GLPAPPRVIK ARGGSQPGEL QIHWEAPAPE ISDFLRHEL R YGPTDSSNAT
APSVIQLLST ETCCPTLWMP NPVPVLDQPP CVHPTASQPH GPAPFLT VKG GSCLVSGLQA
SKSYWLQLRS QPDGVSLRGS WGPWSFPVTV DLPGDAVTIG LQCFTLDLKM VTCQWQQQDR
TSSQGFFRHS RTRCCPTDRD PTWEKCEEEE PRPGSQPALV SRCHF KSRND SVIHILVEVT
TAQGAVHSYL GSPFWIHQAV LLPTPSLHWR EVSSGRLELE WQHQSSWAAQ ETCYQLRYTG
EGREDWKVLE PSLGARGGTL ELRPRARYSL QLRARLNGPT YQGPWSAWSP PARVSTGSET
AWITLVTALL LVLSLSALLG LLLLKWQFPA HYRRLRHALW PSLPDLHRVL GQYLRDTAAL
SPSKATVTDS CEEVEPSLLE ILPKSSESTP LPLCPSQPQM DYRGLQPCLR TMPLSVCPPM
AETGSCCTTH IANHSYLPLS YWQQP

Figure 5




Figure 6





Figure 7




Figure 8




Figure 9




Figure 10




Figure 11







Figure 12


a)



b)




c)




Figures 13a, b, c & d

a)




b)



(c)


name	sequence
scrambled	CLPLSGPDSHIRGPL
Ser585Ala	CLGPPHSRALPDILG
non-phospho-Ser585	CLGPPHSRSLPDILG
phospho-Ser585	CLGPPHSRSLPDILG

(d)




Figures 14a & b

a)




b)



Figures 15a & b

a)



b)




Figure 16

a)

	wt β_c		β_c HSRSLP \rightarrow EFAAAA	
	G ₀ /G ₁	S + G ₂ /M	G ₀ /G ₁	S + G ₂ /M
asynchronous cells	37.3	62.7	36.0	64.0
starved	88.3	11.7	87.4	12.6
+ IL-3	64.7	35.3	64.3	35.7




Figure 17




Figure 18




Figure 19

